Three newly published studies demonstrate Invokana (canagliflozin) produces improvements in type 2 diabetes- Janssen Pharmaceuticals

Results from three separate data analyses representing diverse patient populations from real-world clinical practice show that use of the once-daily oral medication Invokana (canagliflozin), from Janssen Pharmaceuticals, is associated with significant improvements in blood glucose control (A1C) in adults with type 2 diabetes, even though most patients were already being managed with other blood-glucose-lowering medications, including insulin.

Analyses over a six-month period showed that, among the 4,017 patients who initially used Invokana, 80 percent of those patients were receiving treatment with other A1C-lowering medications. Of this subset, approximately 20 percent discontinued one or more of those treatments after starting treatment with Invokana. One of these analyses showed Hispanic and Latino Americans – a group at high risk for developing type 2 diabetes and related complications – had higher baseline A1C levels compared to non-Hispanic and non-Latino Americans, and had average A1C reductions greater than 1 percent with Invokana.

Findings from a third analysis showed a large proportion of patients achieved A1C and blood pressure goals and a reduction in body weight three months after initiating treatment with Invokana and the proportions generally remained stable until the end of the analysis period at 12 months. The new findings were published in recent issues of Current Medical Research & Opinion and BMC Endocrine Disorders.